- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06439823
Controlled Study of Upper and Lower Limb Movements in Patients Patients with Pathologies That Have an Impact on Ambulation or Motor Function
February 10, 2025 updated by: Laurent Servais
Controlled Study of Upper and Lower Limb Movements in Patients Patients with Pathologies That Have an Impact on Ambulation or Motor Function to Validate Signal Analysis Algorithms for Wearable Devices Using Magneto-inertial Technology
The main aim of the study is to validate the algorithms developed to analyze the signals from the various sensors contained in the magneto-inertial control units and reconstruct upper and lower limb movements under different normal and pathological conditions.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Laurie Medard
- Phone Number: 003243218222
- Email: laurie.medard@citadelle.be
Study Locations
-
-
Liege
-
Liège, Liege, Belgium, 4000
- Recruiting
- CHR Citadelle
-
Contact:
- Laurie Medard
- Phone Number: 003243218222
- Email: laurie.medard@citadelle.be
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Subjects over 2 years old
- Male or female
- Control subjects with no pathologies that have an impact on ambulation or motor function.
- Signed informed consent and, in the case of minors, informed consent signed by the person with parental authority/guardian
Exclusion Criteria:
- Any other previous or present pathology having an impact on current motor or balance function
- Recent surgery or trauma to upper or lower limbs, or major surgery or trauma within 6 months of inclusion.
- For control subjects, athlete of at least national level.
- Pregnant or breast-feeding women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patient with neuromuscular disease or control subjects
Patients and controls will be examined by a neuropediatric or neurologist.
they will perform upper and lower limb assessments in a walking laboratory.
this study comprises a single session per patient/control subject.
|
Subjects will be equipped with magneto-inertial sensors (ActiMyo®/Syde®) and passive reflective markers belonging to the MoCap® motion capture system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
step length and distance
Time Frame: 36 months
|
Validate the algorithms developed to analyze the signals from the various sensors contained in magneto-inertial control units and reconstruct upper and lower limb movements.
|
36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 24, 2022
Primary Completion (Estimated)
August 1, 2028
Study Completion (Estimated)
August 1, 2028
Study Registration Dates
First Submitted
May 28, 2024
First Submitted That Met QC Criteria
May 31, 2024
First Posted (Actual)
June 3, 2024
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
February 10, 2025
Last Verified
February 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MoCAP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuromuscular Diseases
-
Brugmann University HospitalCompletedAnesthesia, General | Neuromuscular Transmission DisordersBelgium
-
Virginia Commonwealth UniversityRecruitingNeuromuscular Diseases | Neuromuscular Disorder | Neuromuscular Diseases in ChildrenUnited States
-
University Hospital, ToursCompletedNeuromuscular Diseases in Children | Neuromuscular Diseases in InfantsFrance
-
Northwestern UniversityRecruiting
-
Ankara City Hospital BilkentNot yet recruitingNeuromuscular Blockade | Neuromuscular Monitoring | Statin-Associated Myopathy
-
MarsiBionicsHospital Universitario La PazNot yet recruitingNeuromuscular DisordersSpain
-
Ottawa Hospital Research InstituteEnrolling by invitation
-
University of FloridaTerminated
-
Penwest Pharmaceuticals Co.TerminatedNeuromuscular DiseaseUnited Kingdom
Clinical Trials on ActiMyo®/Syde®
-
Centre Hospitalier Universitaire de LiegeSYSNAVRecruitingDuchenne Muscular Dystrophy | Myotonic Dystrophy 1 | Congenital Muscular Dystrophy | Centronuclear Myopathy | Charcot-Marie-Tooth | Fascioscapulohumeral Muscular DystrophyBelgium, Egypt, Hungary, Poland, Romania, Slovenia, Czechia
-
SYSNAVTerminated
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Chong Kun Dang PharmaceuticalCompleted
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Diphtheria | PolioUnited States
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownFunctional DyspepsiaKorea, Republic of
-
Amir AzarpazhoohInstitut Straumann AGCompletedPeriodontal Inflammation | Crown LengtheningCanada
-
Novartis PharmaceuticalsCompletedPulmonary Disease, Chronic Obstructive (COPD)Argentina